Beta amyloid market prospects still no clearer after AAIC analyses
This article was originally published in Scrip
Executive Summary
Biogen and Eli Lilly both presented much-anticipated data at the 2015 Alzheimer's Association International Conference (AAIC) in Washington DC for their respective anti-beta amyloid antibodies aducanumab and solanezumab. While these data continue to support the drugs'' clinical profiles and further development – which Biogen and Eli Lilly are already committed to – there was no further information that might help more accurately gauge each drug''s likelihood of success in Phase III and potential commercial opportunity, says Datamonitor Healthcare analyst Daniel Chancellor.